Literature DB >> 25806797

Risks for nonaffective psychotic disorder and bipolar disorder in young people with autism spectrum disorder: a population-based study.

Jean-Paul Selten1, Michael Lundberg2, Dheeraj Rai3, Cecilia Magnusson2.   

Abstract

IMPORTANCE: Whether individuals with autism spectrum disorder (ASD) are at increased risk for nonaffective psychotic disorder (NAPD) or bipolar disorder (BD) is unknown.
OBJECTIVE: To test whether the risks for NAPD and BD in individuals with ASD are increased and whether these risks are higher than those of their siblings not diagnosed as having ASD. DESIGN, SETTING, AND PARTICIPANTS: We performed a nested case-control study of all individuals 17 years or younger who ever resided in Stockholm County, Sweden, from January 1, 2001, through December 31, 2011 (Stockholm Youth Cohort). We included cohort members ever diagnosed as having ASD (n = 9062) and their full siblings never diagnosed as having ASD. Each case was matched with 10 control individuals of the same sex born during the same month and year. Using Swedish registers, cases, siblings, and controls were followed up until December 31, 2011. By then, the oldest individuals had reached the age of 27 years. EXPOSURES: Autism spectrum disorder, registered before age 16 or 28 years. We distinguished between ASD with and without intellectual disability (ID). MAIN OUTCOMES AND MEASURES: We calculated odds ratios (ORs) for NAPD and BD adjusted for age, sex, population density of place of birth, personal or parental history of migration, hearing impairment, parental age, parental income, parental educational level, and parental history of psychiatric disorder.
RESULTS: The adjusted ORs for NAPD and BD for cases with non-ID ASD registered before age 16 years were 5.6 (95% CI, 3.3-8.5) and 5.8 (95% CI, 3.9-8.7), respectively; the adjusted ORs for cases with ID ASD were 3.5 (95% CI, 2.0-6.0) and 1.8 (95% CI, 0.8-4.1). The adjusted ORs for NAPD and BD in cases with non-ID ASD registered before age 28 years were 12.3 (95% CI, 9.5-15.9) and 8.5 (95% CI, 6.5-11.2), respectively; for cases with ID ASD, these ORs were 6.4 (95% CI, 4.2-9.8) and 2.0 (95% CI, 1.0-3.9), respectively. The ORs for NAPD and BD for the nonautistic full siblings of cases for whom ASD was registered before age 16 years, adjusted for hearing loss, were 1.8 (95% CI, 1.1-2.7) and 1.7 (95% CI, 1.1-2.6), respectively. CONCLUSIONS AND RELEVANCE: A diagnosis of ASD is associated with a substantially increased risk for NAPD and BD. This finding contributes to our understanding of these disorders and has implications for the management of ASD.

Entities:  

Mesh:

Year:  2015        PMID: 25806797     DOI: 10.1001/jamapsychiatry.2014.3059

Source DB:  PubMed          Journal:  JAMA Psychiatry        ISSN: 2168-622X            Impact factor:   21.596


  28 in total

1.  Early Psychosis.

Authors: 
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2021-05-01

2.  Longitudinal Course of Bipolar Disorder in Youth With High-Functioning Autism Spectrum Disorder.

Authors:  Xenia Borue; Carla Mazefsky; Brian T Rooks; Michael Strober; Martin B Keller; Heather Hower; Shirley Yen; Mary Kay Gill; Rasim S Diler; David A Axelson; Benjamin I Goldstein; Tina R Goldstein; Neal Ryan; Fangzi Liao; Jeffrey I Hunt; Daniel P Dickstein; Boris Birmaher
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2016-10-04       Impact factor: 8.829

3.  Interventions based on early intensive applied behaviour analysis for autistic children: a systematic review and cost-effectiveness analysis.

Authors:  Mark Rodgers; David Marshall; Mark Simmonds; Ann Le Couteur; Mousumi Biswas; Kath Wright; Dheeraj Rai; Stephen Palmer; Lesley Stewart; Robert Hodgson
Journal:  Health Technol Assess       Date:  2020-07       Impact factor: 4.014

Review 4.  Developmental Differences Between Schizophrenia and Bipolar Disorder.

Authors:  Mara Parellada; Sandra Gomez-Vallejo; Monica Burdeus; Celso Arango
Journal:  Schizophr Bull       Date:  2017-10-21       Impact factor: 9.306

5.  Clinical Profiles and Conversion Rates Among Young Individuals With Autism Spectrum Disorder Who Present to Clinical High Risk for Psychosis Services.

Authors:  Jennifer H Foss-Feig; Eva Velthorst; Lauren Smith; Abraham Reichenberg; Jean Addington; Kristin S Cadenhead; Barbara A Cornblatt; Daniel H Mathalon; Thomas H McGlashan; Diana O Perkins; Larry J Seidman; William S Stone; Matcheri Keshavan; Ming T Tsuang; Elaine F Walker; Scott W Woods; Tyrone D Cannon; Carrie E Bearden
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2019-02-20       Impact factor: 8.829

Review 6.  A genetics-first approach to understanding autism and schizophrenia spectrum disorders: the 22q11.2 deletion syndrome.

Authors:  Ania M Fiksinski; Gil D Hoftman; Jacob A S Vorstman; Carrie E Bearden
Journal:  Mol Psychiatry       Date:  2022-10-03       Impact factor: 13.437

7.  A Meta-Analysis of Autism and Clinical High-Risk for Psychosis is Too Premature. Comment on: Vaquerizo-Serrano, Salazar de Pablo, Singh & Santosh (2021).

Authors:  Tim Ziermans; Annabeth Groenman; Rik Schalbroeck
Journal:  J Autism Dev Disord       Date:  2021-11-05

8.  Exome Sequencing of Familial Bipolar Disorder.

Authors:  Fernando S Goes; Mehdi Pirooznia; Jennifer S Parla; Melissa Kramer; Elena Ghiban; Senem Mavruk; Yun-Ching Chen; Eric T Monson; Virginia L Willour; Rachel Karchin; Matthew Flickinger; Adam E Locke; Shawn E Levy; Laura J Scott; Michael Boehnke; Eli Stahl; Jennifer L Moran; Christina M Hultman; Mikael Landén; Shaun M Purcell; Pamela Sklar; Peter P Zandi; W Richard McCombie; James B Potash
Journal:  JAMA Psychiatry       Date:  2016-06-01       Impact factor: 21.596

9.  Reported autism diagnosis is associated with psychotic-like symptoms in the Adolescent Brain Cognitive Development cohort.

Authors:  Amandeep Jutla; Meghan Rose Donohue; Jeremy Veenstra-VanderWeele; Jennifer H Foss-Feig
Journal:  Eur Child Adolesc Psychiatry       Date:  2021-03-01       Impact factor: 5.349

Review 10.  Neuroimaging Heterogeneity in Psychosis: Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic Innovation.

Authors:  Aristotle N Voineskos; Grace R Jacobs; Stephanie H Ameis
Journal:  Biol Psychiatry       Date:  2019-09-17       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.